Health Care & Life Sciences » Biotechnology | Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
7,000.00
10,825.00
13,680.00
31,983.00
60,641.00
Cost of Goods Sold (COGS) incl. D&A
-
801.00
7,240.00
67,294.00
28,498.00
Gross Income
-
10,024.00
6,440.00
35,311.00
32,143.00
SG&A Expense
53,029.00
121,253.00
117,508.00
113,052.00
137,301.00
EBIT
46,083.00
111,229.00
111,068.00
122,763.00
101,691.00
Unusual Expense
1,000.00
-
1,102.00
4,718.00
5,000.00
Non Operating Income/Expense
161.00
121.00
-
23.00
4,726.00
Interest Expense
-
-
11,357.00
34,209.00
62,965.00
Pretax Income
46,732.00
110,818.00
123,055.00
161,015.00
163,675.00
Income Tax
-
700.00
90.00
80.00
235.00
Consolidated Net Income
46,732.00
111,518.00
123,145.00
161,095.00
163,440.00
Net Income
46,732.00
111,518.00
123,145.00
161,095.00
163,440.00
Net Income After Extraordinaries
46,732.00
111,518.00
123,145.00
161,095.00
163,440.00
Net Income Available to Common
46,732.00
111,518.00
123,145.00
161,095.00
163,440.00
EPS (Basic)
0.58
1.23
1.19
1.52
1.43
Basic Shares Outstanding
81,009.60
91,000.90
103,898.40
105,845.10
114,507.70
EPS (Diluted)
0.58
1.23
1.19
1.52
1.43
Diluted Shares Outstanding
81,009.60
91,000.90
103,898.40
105,845.10
114,507.70
EBITDA
46,029.00
110,923.00
110,472.00
121,758.00
100,754.00
Other Operating Expense
-
-
-
25,600.00
3,467.00
Non-Operating Interest Income
190.00
290.00
472.00
698.00
707.00

About Keryx Biopharmaceuticals

View Profile
Address
12th Floor
Boston Massachusetts 02210
United States
Employees -
Website http://www.keryx.com
Updated 09/14/2018
Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases. Its product is the Auryxia tablet. The company was founded in October 1998 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.